GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis

• Published in: Journal of allergy and clinical immunology Vol. 144; no. 2; pp. 482 - 493.e7
• Main Authors: Guttman-Yassky, Emma, Pavel, Ana B., Zhou, Lisa, Estrada, Yeriel D., Zhang, Ning, Xu, Hui, Peng, Xiangyu, Wen, Huei-Chi, Govas, Panayiota, Gudi, Girish, CA, Vinu, Fang, Hui, Salhi, Yacine, Back, Jonathan, Reddy, Venkateshwar, Bissonnette, Robert, Maari, Catherine, Grossman, Fred, Wolff, Gerhard
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2019; Elsevier Limited
• Subjects: Adult; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Apoptosis; Atopic dermatitis; biomarkers; Biopsy; CCL17 protein; costimulation; CXCL10 protein; Cytokines; Cytokines - immunology; Dendritic cells; Dermatitis; Dermatitis, Atopic - drug therapy; Dermatitis, Atopic - immunology; Dermatitis, Atopic - pathology; Eczema; FDA approval; Female; Gene expression; Gene Expression Regulation - drug effects; Gene Expression Regulation - immunology; Helper cells; Humans; Hyperplasia; Hyperplasia - immunology; Hyperplasia - pathology; inflammation; Interleukin 8; Intravenous administration; Keratin; Lymphocytes; Lymphocytes T; Male; Middle Aged; Monoclonal antibodies; OX40; Ox40L protein; Patients; Population; Pruritus; Psoriasis; Receptors, OX40 - antagonists & inhibitors; Receptors, OX40 - immunology; Skin; Skin - immunology; Skin - pathology; Skin diseases; TH1; TH17/TH22; TH2; trial; γ-Interferon; United States > US; OX40; DLQI; OX40L; ITT; trial; NRS; BSA; EASI; costimulation; Atopic dermatitis; inflammation; hyperplasia; SCORAD; IGA; AD; TSLP; biomarkers; TSLPR; K16; TEAE; BAS; TH17/TH22; TH1; Foxp3; TH2; DC; T(H)17/T(H)22; T(H)1; T(H)2

GBR 830 is a humanized mAb against OX40, a costimulatory receptor on activated T cells. OX40 inhibition might have a therapeutic role in T cell–mediated diseases, including atopic dermatitis (AD). This exploratory phase 2a study investigated the safety, efficacy, and tissue effects of GBR 830 in pat...